INS, intranasal steroid.
*Compared with other steroid allergy sprays, on day 1.
†On day 1.
‡INS onset based on various product information; time to maximum efficacy depends on the INS brand.
§In a survey of allergy patients that included nasal spray users (n=732), 42% of patients said they administer their INS “some days and not others.”12
||Up to twice daily.
1. Hsu S-N, Stevens DA, Sajjad F, Salapatek AM. Onset of action of azelastine HCl nasal spray 0.15% evaluated in an environmental exposure chamber. Poster presented at: ACAAI Annual Scientific Meeting; November 10-14, 2022; Louisville, KY. 2. Flonase® website. Accessed June 13, 2023. https://www.flonase.com/faqs/ 3. Flonase®. Prescribing Information. GlaxoSmithKline; 2019. 4. Haleon Health Partner website. Accessed June 13, 2023. https://www.haleonhealthpartner.com/en-us/respiratory-health/brands/flonase-products/flonase/dosing-administration-flonase-allergy-relief/ 5. Nasacort® website. Accessed June 13, 2023. https://www.nasacort.com/allergy-nasal-spray 6. Nasacort® AQ. Prescribing information. Sanofi-aventis U.S. LLC; 2008. 7. Budesonide Nasal Spray. Prescribing information. Apotex Inc.; 2011. 8. Shah S, Berger W, Lumry W, La Force C, Wheeler W, Sacks H. Efficacy and safety of azelastine 0.15% nasal spray and azelastine 0.10% nasal spray in patients with seasonal allergic rhinitis. Allergy Asthma Proc. 2009;30(6):628-633. doi:10.2500/aap.2009.30.3296 9. NDA 213872. 10. FDA approves a nasal antihistamine for nonprescription use. Approval is a first-in-class and was enabled by the prescription to nonprescription switch process. News release. FDA; June 17, 2021. Accessed June 13, 2023. https://www.fda.gov/news-events/press-announcements/fda-approves-nasal-antihistamine-nonprescription-use 11. Data on file. Bayer. IRI data. Only OTC AH. 12. Data on file. Bayer. Habits and practices. 13. Ortiz G, Knudtson M. Counseling patients on the use of intransal steroids in allergic rhinitis management. Consultant. 2017;57(6):328-334. 14. Flonase® Drug Facts Label. NDA205434. 15. Nasacort® Drug Facts Label. NDA020468. 16. Astepro®. Prescribing information. Meda Pharmaceuticals Inc; 2018. 17. US Department of Health and Human Services. Pediatric Postmarketing Pharmacovigilance and Drug Utilization Review. November 3, 2016. Accessed June 13, 2023. 18. Astelin. Prescribing information. Meda Pharmaceuticals Inc; 2014. 19. van Bavel J, Howland WC, Amar NJ, Wheeler W, Sacks H. Efficacy and safety of azelastine 0.15% nasal spray administered once daily in subjects with seasonal allergic rhinitis. Allergy Asthma Proc. 2009;30(5):512-518. doi:10.2500/aap.2009.30.3284